NPS IND dashboard

4 open chemical decisions

Lys position

Lys11HomoLysHomoHomoLysOrnithineLys12

v40.22 (Lys11) vs v40.9 (HomoLys11) head-to-head; v40.24 / v40.25 extra reach reads

KAN-87 KAN-88

Chain length

C16C18 satC18:1C20

C16 over-covered. v40.4 reads C18:1. C20 + saturated C18 are KAN gap-fills.

KAN-90 KAN-92

Truncation

1-201-131-12

Covered on both Nle11 (v40.2 / v40.3) and HomoLys11 (v40.10 / v40.11) scaffolds.

no linked tickets

C-terminus

-NH2-OH (free acid)

Only -NH2 in current queue. -OH gap-fill filed.

KAN-91

IND stages at a glance

Stage	Open	Overdue	Next due
Lead optimization	12	0	2026-07-06
Stability + degradation	2	0	2026-08-14
PK (methods · studies · scaling/HED · PK-PD)	23	3	2026-06-26
Safety + immunogenicity	4	0	2026-07-21
GLP / CMC outsourcing	8	0	2026-09-08
Regulatory (AU CTN)	3	0	2026-09-15

Active studies (preclin.study, last 30 days)

STU-olden-dl-dmuo-st0067 · executing

NPSv40.9 1000ug vs. NPSv40.9 500ug vs. NPSv40.9 200ug vs. NPSv40.9 100ug vs. Placebo, subq, 100ul, 0.9% saline, n = 15

owner: — · updated 2026-07-01 17:31:00.823475+00:00

STU-olden-np-ghb8-st0030 · executing

AMENv1 (500ug) vs. NPS x OXN x aMCH Co-dosed at equimolar vs. NPS (equimolar) vs. OXN (equimolar) vs. aMCH (equimolar) vs. Placebo, subQ, all in 100mM NaHCO3, n = 20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-zaqi-st0068 · executing

NPSv16.1 vs NPSv16.3 vs Placebo

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-ddeu-st0099 · executing

NPSv16.3 vs. NPSv16.4 vs. NPSv18.37 vs. NPSv18.43 vs. NPSv18.47 vs. NPSv18.48 vs. NPSv34.29 vs. Placebo, 100ug, IN, 0.5% TMC, n = 20, ns.

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-90eg-st0012 · executing

NPSv17.1 vs. NPSv17.2 vs. NPSv17.3 vs. NPSv17.4 vs. NPSv2 vs. Placebo, IN (0.25% TMC), 50ug, n=20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-xnje-st0007 · executing

NPSv16.10 vs. NPSv16.6 vs. NPSv16.7 vs. NPSv2

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-3wjh-st0039 · executing

V1 in House NPS4.2 vs Placebo

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-meho-st0043 · executing

NPSv9.36 1mg vs. NPSv9.16 1mg vs. NPSv5.2 1mg vs. NPSv3.1 1mg vs. Placebo, subQ, 100uL saline

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-4qgd-st0002 · executing

NPSv9.36 vs NPSv9.16

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-tn5g-st0065 · executing

NPSv9.7 vs NPSv9.16 vs Placebo

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-zd8h-st0055 · executing

NPSv9.7 vs NPSv9.5 vs NPSv1

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-pqor-st0027 · executing

NPSV v1 50nmol 5 cages

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-dl-7yav-st0023 · executing

OXNv27.4 vs. OXNv28.2 vs. NPSv40.18 vs. NPSv40.19 vs. OXNv16.22 vs. Placebo, IN, 0.25% TMC, n = 20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-oh5f-st0046 · executing

proNPS

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-9rtv-st0050 · executing

Pro-NPS Experiments (NPSv1-proKKv1 vs - NPSv1-proNTv1 vs NPS)

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-ixsq-st0022 · executing

proNPSv1K8 (20ug, 100ug) vs. proNPSv2KK (20ug, 100ug) vs. proNPSv2NT (20ug, 100ug) vs. Placebo, 0.25% TMC, IN, n = 20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-z563-st0019 · executing

proNPSv2KK (100ug) vs proNPSv2KK (500ug) vs proNPSv2NT (100ug) vs MOXv1 (100ug) vs MOXv1 (500ug) vs Caff (100ug) vs Plac (saline), IN, n = 20, 0.25% TMC

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-tojy-st0062 · executing

Subq - (OXA vs NPSv5.2 vs Caffeine)

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-bdwq-st0042 · executing

TAK 861 vs TAK 861+NPS v5.2

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-lsdo-st0047 · executing

500ug NPSv2-proNTv1 vs. 500ug NPSv2-proKKv1 vs. 500ug NPSv1-proK8v1 vs. 500ug NPSv1-proNTv1 vs. Placebo, n = 25

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-gtsn-st0087 · executing

500ug NPSv2-proNTv1 vs. 500ug NPSv2-proKKv1 vs. 500ug NPSv1-proK8v1 vs. 500ug NPSv1-proNTv1 vs. Placebo, n = 25

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-dl-arpa-st0046 · executing

EEG NPSv40.10 100ug vs. Placebo, IN, Olden actigraphy, n = 5

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-dl-cxt2-st0058 · executing

EEG NPSv40.9 100ug vs. Placebo, IN, Olden actigraphy, n = 4

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-vi2s-st0107 · executing

NPS17.5 IN 50ug vs. NPS17.5 IN 100ug vs. NPS17.5 SC 250ug vs. NPS17.5 SC 500ug vs. Veh IN vs. Veh SC, n = 5

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-wld9-st0061 · executing

OXNv2 + NPSv5.2 + AZD1979 + GLP3970

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-zzsy-st0063 · executing

NPSv10.13 vs NPSv10.15 vs NPSv10.1 vs NPSv10.6 vs NPSv10.14 vs Placebo (0.9% Saline)

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-nd-ucip-st0003 · executing

NPSv14 vs NPSv5.2 vs Placebo

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-nd-rrpy-st0004 · executing

NPSv14 vs NPSv5.2 vs Placebo - New Cages

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-t5of-st0008 · executing

NPSv16.11 (high vs. low) vs. NPSv2

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-ut9j-st0026 · executing

NPSv17.3 (100ug) vs. NPSv17.3 (50ug) vs. NPSv17.3 (10ug) vs. NPSv17.3 (1ug) vs. Placebo, IN, 0.25% TMC, n = 20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-eqk3-st0013 · executing

NPSv18.2 (IN 0.25% TMC) vs. NPSv18.2 (subcutaneous) vs. Placebo, 100ug, n=20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-pkne-st0011 · executing

NPSv18.2 vs. NPSv18.4 vs. NPSv18.6 vs. NPSv18.9 vs. NPSv2 vs. Placebo, IN (0.25% TMC), 50ug, n=25

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-f4vg-st0095 · executing

NPSv18.43 100ug vs. NPSv18.47 100ug vs. NPSv18.48 100ug vs. Placebo, IN, 0.25% TMC, n = 20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-oz8t-st0049 · executing

NPSv1-proNTv1 Dose finding

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-vbqo-st0101 · executing

NPSv1 vs. NPSv2 vs. NPSv3 vs. NPSv4 vs. Placebo, 100ug IN, 0.25% TMC, n = 20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-vkmq-st0074 · executing

NPSv20.1 vs NPSv20.2 vs Placebo

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-de9m-st0034 · executing

NPS v2 TMC vs non TMC (Anesthesia)

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-yc4g-st0040 · executing

NPS v2 vs NPS v5.2 (100ug) vs placebo

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-dl-p7x1-st0045 · executing

NPSv37.4 100ug 0.25% TMC vs. NPSv37.4 100ug 0.5% TMC vs. NPSv37.4 100ug 2.5% cyclodextrin vs. NPSv37.4 100ug 5% cyclodextrin vs. Vehicle 0.25% TMC vs. Vehicle 5% cyclodextrin, IN, 10uL, n = 20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-drt1-st0035 · executing

NPSv2 vs v3 A/TMC

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-mxzv-st0094 · executing

NPSv33.4 100ug vs. NPSv33.6 100ug vs. NPSv34.6 100ug vs. NPSv34.15 100ug vs. NPSv34.25 100ug vs. NPSv34.33 100ug vs. Placebo, IN, 0.25% TMC, n = 20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-l9ns-st0075 · executing

NPsv34.1 (100ug) vs NPsv34.3 (100ug) vs NPsv34.8 (100ug) NPsv34.8 (50ug) vs NPSv17.4 (100ug) vs Placebo

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-zw69-st0091 · executing

NPSv34.31 vs. NPSv34.29 vs. NPSv34.28 vs. NPSv34.26 vs. NPSv34.13 vs. NPSv34.7 vs. NPSv17.6 vs. Placebo, subQ, 1mg, 100mM NaHCO3, n = 15

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-7eip-st0029 · executing

NPSv34.6 (40ug) vs. NPSv34.7 (40ug) vs. NPSv34.8 (40ug) vs. NPSv34.9 (40ug) vs. Placebo (0.25% TMC), IN, n = 20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-byln-st0093 · executing

NPSv34.7 100ug vs. NPSv34.26 100ug vs. NPSv34.29 100ug vs. MOXv2.1 200ug vs. OXB 135ug vs. Placebo, IN, 0.25% TMC, n = 20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-dl-w3um-st0043 · executing

NPSv40.19 25ug vs. NPSv40.19 50ug vs. NPSv40.19 100ug vs. NPSv40.19 200ug vs. Placebo, IN, 0.25% TMC, 10uL, n = 15

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-dl-bnkz-st0003 · executing

NPSv40.2 100ug vs. NPSv40.17 100ug vs. NPSv40.3 100ug vs. NPSv40.5 100ug vs. Placebo, IN, 100ug, 0.25% TMC, 5% HP-beta-cyclodextrin, n = 20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-dl-wd2o-st0042 · executing

NPSv40.7 50ug 5mgmL vs. NPSv40.7 100ug 10mgmL vs. NPSv40.7 200ug 20mgmL vs. NPSv40.7 800ug 80mgmL vs. Placebo, IN, 10uL, n = 15

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-dl-qmlo-st0075 · executing

NPSv40.9 1000ug vs. NPSv40.9 500ug vs. NPSv41.7 1000ug vs. NPSv41.7 500ug vs. Placebo, subq, n = 15

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-dl-nbtc-st0044 · executing

NPSv40.9 25ug vs. NPSv40.9 50ug vs. NPSv40.9 100ug vs. NPSv40.9 200ug vs. Placebo, IN, 0.25% TMC, 10uL, n = 15

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-if-gf6g-st0018 · executing

OXNv3.1 / NPSv2 / NPSv2 + OXNv3.1

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-dl-hga4-st0078 · executing

NPSv41.18 500ug vs. NPSv41.13 500ug vs. NPSv40.9 500ug vs. Placebo, SQ, 0.9% saline, n = 15

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-dl-fswz-st0077 · executing

NPSv41.21 500ug vs. NPSv41.12 500ug vs. NPSv41.8 500ug vs. Placebo, 0.9% saline, subQ, n = 15

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-dl-lr5i-st0076 · executing

NPSv41.8 500ug vs. NPSv41.20 500ug vs. Placebo, 0.9% saline, SQ, n = 15

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-dl-ixox-st0031 · executing

NPSv50 vs. Placebo, n = 20

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-vbmo-st0032 · executing

NPSv5.2 (500ug) vs NPSv9.16 (500ug) vs NPSv9.36 (500ug) vs Caffeine (500ug) vs OXNv20.2 (500ug vs OXNv22.14 (500ug) vs. Placebo, subQ, NaHCO3, 100uL

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-np-mzap-st0018 · executing

NPSv5.2 dose finding (1ug/10ug/50ug/100ug) vs. NPSv34.3 (50ug) vs. Placebo, IN (0.25% TMC), n = 25

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-pxbu-st0041 · executing

NPSv5.2+OXN (combined, IN) 3.1 vs TAK 861 (oral gavage) vs Placebo (oral gavage)(100ug/mouse [all drugs])

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-zq1d-st0070 · executing

NPSv5.2 subq dose-finding (50ug/100ug/500ug)

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-vre1-st0069 · executing

NPSv5.2 vs TAK861 vs BMS_peak2 vs SK124

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-kn1w-st0060 · executing

NPSv5.3 vs Placebo -- multi-day repeated dosing

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-svxg-st0059 · executing

NPSv5.3 vs. Placebo vs. NPSv5.2 vs. RTI118

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-wlyq-st0057 · executing

NPSv5.3 vs SuperOXBv1 vs OXNv2

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-vpv4-st0064 · executing

NPSv9.15 vs NPSv9.36 vs Placebo

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-26-NPS-20260629-001 · locked · KAN-87

Lead-lock same-plate IP1 for NPSR1 107I and 107N coverage

Determine whether the apparent 107I lead candidates retain potent full agonism on both hNPSR1 107I and 107N under matched-plate conditions, vs the prior split-plate readouts.

owner: iris · updated 2026-06-30 23:23:21.099559+00:00

STU-26-NPS-20260629-003 · locked · KAN-89

Accelerated LC-MS stability triage for NPS lead-lock pair

Identify rapid parent loss or route-relevant degradation liabilities in the top NPS lead-lock candidates before the 2026-07-06 decision.

owner: iris · updated 2026-06-30 02:53:17.085537+00:00

STU-26-NPS-20260629-002 · locked · KAN-88

Human albumin functional-shift screen for lipidated NPS leaders

Test whether top lipidated NPS candidates preserve functional NPSR1 agonism in human albumin conditions relevant to human half-life translation.

owner: iris · updated 2026-06-30 02:23:56.962000+00:00

STU-26-NPS-20260630-002 · draft · KAN-109

Same-plate IP1 and beta-arrestin separation screen for v40 leaders

Test whether the top v40 IP1 leaders retain active Gq/IP1 signaling while avoiding strong beta-arrestin potency or high beta-arrestin Emax.

owner: iris · updated 2026-06-30 23:03:08.797599+00:00

STU-26-NPS-20260630-001 · draft · KAN-108

Same-plate 107I/107N IP1 bridge for NPSv40.24 lead inclusion

Determine whether NPSv40.24 reproducibly matches or exceeds NPSv40.22 and NPSv40.9 on both hNPSR1 107I and 107N IP1 potency and Emax.

owner: iris · updated 2026-06-30 23:02:57.825929+00:00

STU-olden-hr-hwhc-st0023 · complete

NPS v2 10nmol/25nmol/50nmol/Caffeine

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-tvna-st0020 · complete

NPS v2 100nmol/10nmol/1nmol/Placebo

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-ibpx-st0028 · complete

NPSv 1 50/100/500nmol

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-crit-st0012 · complete

[100x Underdosed] OXN v2 vs NPS V1 vs NPS V1+OXN V2

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-p3hh-st0007 · complete

[100x Underdosed] NPS 2 OXN 2 OXN 3

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-odrq-st0025 · complete

NPS v2 50nmol night trial

owner: — · updated 2026-07-01 17:16:07.577204+00:00

STU-olden-hr-x16t-st0017 · complete

NPS v1 25/50/100NMOL vs Placebo

owner: — · updated 2026-07-01 17:16:07.577204+00:00

Overdue across all stages (6)

Key	Status	Due	Assignee	Vendor	CRO progress	Summary
KAN-20	Idea	2026-06-22	Moaraj Hasan	no vendor	pick vendor (-9d to due)	SPPS synthesis - NPS 40.9
KAN-24	Idea	2026-06-26	Moaraj Hasan	no vendor	pick vendor (-5d to due)	PK study design + AEC (Animal Ethics Committee) protocol (mouse single-dose IV/SC)
KAN-21	Idea	2026-06-26	Moaraj Hasan	no vendor	pick vendor (-5d to due)	RP-HPLC purification + lyophilization (NXN + NPS)
KAN-16	Idea	2026-06-26	Moaraj Hasan	no vendor	pick vendor (-5d to due)	Peptide Synthesis & Purification
KAN-29	Idea	2026-06-30	Moaraj Hasan	no vendor	pick vendor (-1d to due)	Reference standards, IS qualification + stock/working solutions
KAN-25	Idea	2026-06-30	Moaraj Hasan	no vendor	pick vendor (-1d to due)	Dose formulation, dose verification, and vehicle bridging

Compound × complete-assay coverage

"Complete" assay set: 107I IP1 · 107N IP1 · 107I FLIPR · 107N FLIPR · bArr · cAMP — same-plate, same-producer-batch. Cells show best EC50 in nM and run count. Empty cells (—) are missing reads.

Compound	Qty	Synth	In-vitro (cell assays)						In-vivo + stability
Compound	Qty	Synth	IP1 (107I)	IP1 (107N)	FLIPR (107I)	FLIPR (107N)	bArr (107N)	cAMP (107N)	SC actigraphy	EEG	PK plasma	PK CSF/brain	Stability (LC-MS)
`NPSv40.9` ANCHOR · Lead candidate — HomoLys11, 1-20, -NH2 — in all three head-to-heads `SF(Nω-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(γ-E)-(C16 Pal)]-TSFQRAKS-NH2`	not tracked	queued for SPPS	0.00 nM · n=1	0.03 nM · n=2	0.62 nM · n=1	0.17 nM · n=2	1.47 nM · n=3	0.12 nM · n=2	0-6h: -33% sleep (NPSv41.18 500ug) 0-24h: -28% sleep (NPSv41.18 500ug) DL-HGA4-st0078 · 12 Olden runs · latest 2026-06-29	post-lock	post-lock	post-lock	planned
`NPSv40.22` Lys position · Lys11 `SF(Nomega-methyl-Arg)N(Sar)VGTG(N-Me-Nle)K-K[(gamma-E)-(C16 Pal)]-TSFQRAKS-NH2`	—	queued for SPPS	—	0.10 nM · n=1	—	—	—	—	planned	post-lock	post-lock	post-lock	planned
`NPSv40.24` Lys position · HomoHomoLys11 (secondary — extra reach) `SF(Nomega-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoHomoLys)-K[(gamma-E)-(C16 Pal)]-TS…`	not tracked	queued for SPPS	—	—	—	—	1.85 nM · n=1	—	planned	post-lock	post-lock	post-lock	planned
`NPSv40.25` Lys position · Ornithine11 (secondary) `SF(Nomega-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(Orn)-K[(gamma-E)-(C16 Pal)]-TSFQRAKS-N…`	not tracked	through HPLC	—	—	—	—	2.75 nM · n=1	—	planned	post-lock	post-lock	post-lock	planned
`NPSv40.10` Truncation · 1-13 (hypothesis: default 1-20 wins; verify) `SF(Nω-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(γ-E)-(C16 Pal)]-T-NH2`	not tracked	queued for SPPS	—	0.24 nM · n=1	—	—	—	—	0-6h: +22% sleep (EEG NPSv40.10 100ug) 0-24h: +71% sleep (EEG NPSv40.10 100ug) DL-arPA-st0046 · 2 Olden runs · latest 2026-06-01	—	—	—	—
`NPSv40.11` Truncation · 1-12 (hypothesis: default 1-20 wins; verify) `SF(Nω-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(γ-E)-(C16 Pal)]-NH2`	not tracked	through HPLC	—	0.16 nM · n=1	—	—	—	—	planned	—	—	—	—
`NPSv41.1` C-terminus · -OH variant of v40.9 — critical for in-vivo effect-life decision `SF(Nomega-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(gamma-E)-(C16 Pal)]-TSFQRA…`	not tracked	through HPLC	—	—	—	—	—	—	0-6h: -33% sleep (NPSv41.18 500ug) 0-24h: -28% sleep (NPSv41.18 500ug) DL-HGA4-st0078 · 2 Olden runs · latest 2026-06-29	post-lock	post-lock	post-lock	—
`NPSv40.23` Secondary · Nω,Nω-dimethyl-Arg3 — add to cell assays where we have it (lower priority) `SF(Nomega,Nomega-dimethyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(gamma-E)-(C16 Pal…`	not tracked	queued for SPPS	—	1.71 nM · n=1	—	—	4.99 nM · n=1	—	—	—	—	—	—
`NPSv41.12` Chain length · C20 + 1-13 truncation, Lys11 (not HomoLys), -NH2 — in-vivo data in hand `SF(Nomega-methyl-Arg)N(Sar)VGTGMK-K[(gamma-E)-(C20)]-T-NH2`	not tracked	partial	—	—	—	—	15.68 nM · n=1	—	0-6h: -82% sleep (NPSv41.8 500ug) 0-24h: -73% sleep (NPSv41.8 500ug) DL-fsWz-st0077 · 1 Olden runs · latest 2026-06-27	—	—	—	—
`NPSv41.7` Chain length · C20 analog of v40.9 — HomoLys11, 1-20, -NH2 — SC head-to-head vs v40.9 data in hand `SF(Nomega-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(gamma-E)-(C20)]-TSFQRAKS-N…`	not tracked	queued for SPPS	—	—	—	—	—	—	0-6h: -94% sleep (NPSv40.9 500ug) 0-24h: -77% sleep (NPSv41.7 1000ug) DL-QMLo-st0075 · 2 Olden runs · latest 2026-06-25	—	—	—	—
`NPSv41.8` Chain length · C20 + 1-13 truncation, HomoLys11, -NH2 — in-vivo data in hand `SF(Nomega-methyl-Arg)N(Sar)VGTG(N-Me-Nle)(HomoLys)-K[(gamma-E)-(C20)]-T-NH2`	not tracked	queued for SPPS	—	—	—	—	—	—	0-6h: -82% sleep (NPSv41.8 500ug) 0-24h: -73% sleep (NPSv41.8 500ug) DL-fsWz-st0077 · 2 Olden runs · latest 2026-06-27	—	—	—	—

Planned SC mouse studies (@Jigisha)

Study	Arms	Status / note
Lys11 SC study	`NPSv40.9` · `NPSv40.22` · `NPSv40.24` · `NPSv40.25`	@Jigisha — n≥20/group, 1-page plan, verify material first
Truncation SC study	`NPSv40.9` · `NPSv40.10` · `NPSv40.11`	@Jigisha — n≥20/group, 1-page plan, verify material first
C-terminus SC study	`NPSv40.9` · `NPSv41.1`	@Jigisha — critical for finalising -NH2 vs -OH on in-vivo effect-life

Synthesis workstream (@Nico, @Hillary)

Chemistry ask (@Nico): one clean ≥95% pure in-house batch each of v40.9, v40.22, v40.24, v40.25, v41.1.

Key	Status	Due	Assignee	Vendor	CRO progress	Summary
KAN-20	Idea	2026-06-22	Moaraj Hasan	in-house	in-house	SPPS synthesis - NPS 40.9
KAN-21	Idea	2026-06-26	Moaraj Hasan	in-house	in-house	RP-HPLC purification + lyophilization (NXN + NPS)
KAN-16	Idea	2026-06-26	Moaraj Hasan	in-house	in-house	Peptide Synthesis & Purification

Analytical QC workstream (@Mo)

Key	Status	Due	Assignee	Vendor	CRO progress	Summary
KAN-17	Idea	2026-07-03	Moaraj Hasan	in-house	in-house	Analytical QC / Mass Spec ID
KAN-14	Idea	2026-07-03	Moaraj Hasan	in-house	in-house	Intact mass + full sequence confirmation MS/MS

In-vitro potency workstream (@Stephen)

Key	Status	Due	Assignee	Vendor	CRO progress	Summary
KAN-23	Idea	2026-07-17	Moaraj Hasan	in-house	in-house	NPSR1 IP1 EC50 assay — NPS 40.9
KAN-18	Idea	2026-07-17	Moaraj Hasan	in-house	in-house	In-vitro Potency (OX2 IP1 / EC50)

Mechanism + efficacy workstream (in-vitro target engagement, selectivity panel)

Key	Status	Due	Assignee	Vendor	CRO progress	Summary
KAN-40	Idea	2026-07-15	Moaraj Hasan	in-house	in-house	In-vitro target engagement + selectivity panel
KAN-41	Idea	2026-08-05	Moaraj Hasan	in-house	in-house	In-vivo efficacy / target-engagement model (mouse)
KAN-42	Idea	2026-08-31	Moaraj Hasan	in-house	in-house	Mechanism-of-action omics readout + brain exposure
KAN-6	Idea	2026-08-31	Moaraj Hasan	in-house	in-house	Efficacy & Mechanism (cells, mouse, omics)

Filed Iris gap-fills (review needed)

Some of these are now redundant with the 2026-06-30 state-of-the-union — see notes.

KAN	Axis	Status / note
KAN-90	Chain length	C20 lipid analog — realized as NPSv41.7 (HomoLys11) and NPSv41.8/v41.12 (truncated); in-vivo data confirmed, compounds promoted to LEAD_OPT_TABLE
KAN-91	C-terminus	Free-acid (-OH) analog — already in flight as NPSv41.1; close as duplicate
KAN-92	Chain length	Saturated C18 analog — DEFER (future-NPS lever)
KAN-93	CMC	CMC + accelerated-degradation — re-scope as external-contractor work (Helena owns)

Active engagements (3)

Populated from preclin.cro_capability — writes flow from forwarded CRO emails + Slack @iris cro.

Vendor	Workstream	Status	Owner	CRO progress	Last engagement	Notes
Charles River Laboratories	`glp_tox_rodent`	no contract	melissa	no_contract	2026-06-30 📧	CRL BD contact Hank Arrington reached out to initiate CDA or MSA. Moaraj confirm
iHisto Inc.	`histology`	PO	melissa	PO live · Safety tissues shipped to iHisto Inc. (Salem, MA)	2026-06-30 📧	Safety tissues shipped to iHisto Inc. (Salem, MA) via UPS Next Day Air Early on
Charles River Laboratories	`safety_pharm_ich_s7a`	no contract	melissa	no_contract	2026-06-30 📧	CRL engaged to scope full nonclinical package including safety pharmacology as p

Open gaps (17) — KAN tickets with no contracted vendor

KAN	Due	Assignee	Summary
KAN-40	2026-07-15	Moaraj Hasan	In-vitro target engagement + selectivity panel
KAN-43	2026-07-21	Moaraj Hasan	In-vitro safety pharmacology (hERG, cardiovascular liability)
KAN-41	2026-08-05	Moaraj Hasan	In-vivo efficacy / target-engagement model (mouse)
KAN-44	2026-08-10	Moaraj Hasan	Immunogenicity / ADA assay strategy + in-silico risk
KAN-45	2026-08-31	Moaraj Hasan	GLP tox study design + DART deferral justification
KAN-42	2026-08-31	Moaraj Hasan	Mechanism-of-action omics readout + brain exposure
KAN-7	2026-08-31	Moaraj Hasan	Safety & Immunogenicity (DART defer, ADA)
KAN-6	2026-08-31	Moaraj Hasan	Efficacy & Mechanism (cells, mouse, omics)
KAN-71	2026-09-08	Moaraj Hasan	GMP clinical batch manufacture (API) + batch record + CoA
KAN-75	2026-09-15	Moaraj Hasan	Clinical protocol + synopsis (FIH SAD)
KAN-69	2026-09-15	Moaraj Hasan	Genotoxicity battery (Ames + in vitro micronucleus)
KAN-74	2026-09-22	Moaraj Hasan	Author Investigator's Brochure (IB)
KAN-72	2026-09-22	Moaraj Hasan	Drug product CMC: sterile injectable formulation, fill-finish, container-closure
KAN-68	2026-09-22	Moaraj Hasan	GLP repeat-dose toxicology study (non-rodent) - execution + report
KAN-73	2026-09-29	Moaraj Hasan	ICH Q1A stability program on clinical API + DP lots
KAN-9	2026-09-30	Moaraj Hasan	AU CTN Regulatory Package & Submission
KAN-8	2026-09-30	Moaraj Hasan	GLP Outsourcing & CMC (engage on clinical lead)

Stability + degradation

2 open 0 done

CRO progress (Drive): 📁 Manufacturing 📁 Formulation

Key	Status	Due	Assignee	Vendor	CRO progress	Summary
KAN-15	Idea	2026-08-14	Moaraj Hasan	no vendor	pick vendor (44d to due)	Forced degradation study + impurity criteria
KAN-2	Idea	2026-08-14	Moaraj Hasan	no vendor	pick vendor (44d to due)	Degradation & Stability (HF-X Orbitrap)

PK (methods · studies · scaling/HED · PK-PD)

23 open 3 overdue 0 done

CRO progress (Drive): 📁 Preclinical development

Key	Status	Due	Assignee	Vendor	CRO progress	Summary
KAN-24	Idea	2026-06-26	Moaraj Hasan	no vendor	pick vendor (-5d to due)	PK study design + AEC (Animal Ethics Committee) protocol (mouse single-dose IV/SC)
KAN-29	Idea	2026-06-30	Moaraj Hasan	no vendor	pick vendor (-1d to due)	Reference standards, IS qualification + stock/working solutions
KAN-25	Idea	2026-06-30	Moaraj Hasan	no vendor	pick vendor (-1d to due)	Dose formulation, dose verification, and vehicle bridging
KAN-30	Idea	2026-07-08	Moaraj Hasan	no vendor	pick vendor (7d to due)	Calibration curve + selectivity/specificity (ICH M10)
KAN-11	Idea	2026-07-10	Moaraj Hasan	no vendor	pick vendor (9d to due)	6495D MRM method dev - NPS 40.9
KAN-26	Idea	2026-07-10	Moaraj Hasan	no vendor	pick vendor (9d to due)	In-life dosing + serial plasma collection (0-24 h timecourse)
KAN-31	Idea	2026-07-18	Moaraj Hasan	no vendor	pick vendor (17d to due)	Accuracy + precision validation runs (within/between-run)
KAN-27	Idea	2026-07-18	Moaraj Hasan	no vendor	pick vendor (17d to due)	Bioanalysis of PK samples on validated 6495D method
KAN-12	Idea	2026-07-20	Moaraj Hasan	no vendor	pick vendor (19d to due)	Plasma protein binding + blood:plasma partitioning
KAN-32	Idea	2026-07-22	Moaraj Hasan	no vendor	pick vendor (21d to due)	Matrix effect, recovery, dilution integrity, carryover
KAN-35	Idea	2026-07-28	Moaraj Hasan	no vendor	pick vendor (27d to due)	Cross-species in-vitro scaling inputs (clearance, binding, stability)
KAN-28	Idea	2026-07-31	Moaraj Hasan	no vendor	pick vendor (30d to due)	Non-compartmental PK analysis + IV/SC parameter report
KAN-1	Idea	2026-07-31	Moaraj Hasan	no vendor	pick vendor (30d to due)	In-vivo PK: mouse single-dose IV/SC (NXN 20.16 + NPS 40.9)
KAN-13	Idea	2026-08-07	Moaraj Hasan	no vendor	pick vendor (37d to due)	In-vivo PK study report + data package of record (IV/SC)
KAN-33	Idea	2026-08-08	Moaraj Hasan	no vendor	pick vendor (38d to due)	Stability validation (stock, bench, freeze-thaw, long-term, autosampler)
KAN-36	Idea	2026-08-10	Moaraj Hasan	no vendor	pick vendor (40d to due)	Allometric scaling model (CL, Vss) + human PK prediction
KAN-38	Idea	2026-08-10	Moaraj Hasan	no vendor	pick vendor (40d to due)	PK/PD biomarker + exposure-response model build
KAN-37	Idea	2026-08-21	Moaraj Hasan	no vendor	pick vendor (51d to due)	Human starting dose: MABEL + NOAEL/BSA HED + safety factor
KAN-4	Idea	2026-08-21	Moaraj Hasan	no vendor	pick vendor (51d to due)	Allometric Scaling & Human Starting Dose
KAN-34	Idea	2026-08-28	Moaraj Hasan	no vendor	pick vendor (58d to due)	ICH M10 bioanalytical validation report sign-off
KAN-3	Idea	2026-08-28	Moaraj Hasan	no vendor	pick vendor (58d to due)	Bioanalytical Method & ICH M10 Validation (6495D)
KAN-39	Idea	2026-08-28	Moaraj Hasan	no vendor	pick vendor (58d to due)	Clinical dose-escalation scheme + projected exposure margins
KAN-5	Idea	2026-08-28	Moaraj Hasan	no vendor	pick vendor (58d to due)	PK/PD Linkage & Dose Escalation

Safety + immunogenicity

4 open 0 done

CRO progress (Drive): 📁 Tox Studies

Key	Status	Due	Assignee	Vendor	CRO progress	Summary
KAN-43	Idea	2026-07-21	Moaraj Hasan	no vendor	pick vendor (20d to due)	In-vitro safety pharmacology (hERG, cardiovascular liability)
KAN-44	Idea	2026-08-10	Moaraj Hasan	no vendor	pick vendor (40d to due)	Immunogenicity / ADA assay strategy + in-silico risk
KAN-45	Idea	2026-08-31	Moaraj Hasan	no vendor	pick vendor (61d to due)	GLP tox study design + DART deferral justification
KAN-7	Idea	2026-08-31	Moaraj Hasan	no vendor	pick vendor (61d to due)	Safety & Immunogenicity (DART defer, ADA)

GLP / CMC outsourcing

8 open 0 done

CRO progress (Drive): 📁 Manufacturing 📁 Formulation

Key	Status	Due	Assignee	Vendor	CRO progress	Summary
KAN-71	Idea	2026-09-08	Moaraj Hasan	no vendor	pick vendor (69d to due)	GMP clinical batch manufacture (API) + batch record + CoA
KAN-69	Idea	2026-09-15	Moaraj Hasan	no vendor	pick vendor (76d to due)	Genotoxicity battery (Ames + in vitro micronucleus)
KAN-67	Idea	2026-09-15	Moaraj Hasan	Charles River Laboratories · no contract 📧	no_contract	GLP repeat-dose toxicology study (rodent) - execution + report
KAN-72	Idea	2026-09-22	Moaraj Hasan	no vendor	pick vendor (83d to due)	Drug product CMC: sterile injectable formulation, fill-finish, container-closure
KAN-70	Idea	2026-09-22	Moaraj Hasan	Charles River Laboratories · no contract 📧	no_contract	Safety pharmacology core battery (ICH S7A: CV, CNS, respiratory)
KAN-68	Idea	2026-09-22	Moaraj Hasan	no vendor	pick vendor (83d to due)	GLP repeat-dose toxicology study (non-rodent) - execution + report
KAN-73	Idea	2026-09-29	Moaraj Hasan	no vendor	pick vendor (90d to due)	ICH Q1A stability program on clinical API + DP lots
KAN-8	Idea	2026-09-30	Moaraj Hasan	no vendor	pick vendor (91d to due)	GLP Outsourcing & CMC (engage on clinical lead)

Regulatory (AU CTN)

3 open 0 done

CRO progress (Drive): 📁 Phase 1 trial

Key	Status	Due	Assignee	Vendor	CRO progress	Summary
KAN-75	Idea	2026-09-15	Moaraj Hasan	no vendor	pick vendor (76d to due)	Clinical protocol + synopsis (FIH SAD)
KAN-74	In Progress	2026-09-22	Moaraj Hasan	no vendor	pick vendor (83d to due)	Author Investigator's Brochure (IB)
KAN-9	Idea	2026-09-30	Moaraj Hasan	no vendor	pick vendor (91d to due)	AU CTN Regulatory Package & Submission

NPS — IND process tracker

4 open chemical decisions

IND stages at a glance

Active studies (preclin.study, last 30 days)

Overdue across all stages (6)

Compound × complete-assay coverage

Planned SC mouse studies (@Jigisha)

Synthesis workstream (@Nico, @Hillary)

Analytical QC workstream (@Mo)

In-vitro potency workstream (@Stephen)

Mechanism + efficacy workstream (in-vitro target engagement, selectivity panel)

Filed Iris gap-fills (review needed)

Active engagements (3)

Open gaps (17) — KAN tickets with no contracted vendor

Stability + degradation

PK (methods · studies · scaling/HED · PK-PD)

Safety + immunogenicity

GLP / CMC outsourcing

Regulatory (AU CTN)